2019 HCPCS Codes > Q Codes >

Q2040

Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

  • 2019 Status Change: Discontinue procedure or modifier code
  • Effective Date: 2018-01-01
  • Termination Date: 2018-12-31
  • Medicare Coverage Status: Carrier Judgement
  • BETOS Classification: Other drugs

Medicare has not assigned a fee schedule for this code

Q2039       Q2041